Inventiva

Research Inventiva (IVA) on Bullrun: market cap USD 737.15M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIVA
• ExchangeNASDAQ
• CountryFrance
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 737.15M
• Financial periodQ4 2025
• RevenueUSD 4.48M
• Net income-USD 354.14M
• Free cash flow-USD 105.13M

Valuation Snapshot

latest market cap is USD 737.15M.

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.

Frequently asked questions

What is Inventiva's market cap?

Inventiva's market capitalization is USD 737.15M.

What does Inventiva do?

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.